See more : Aspen Digital Inc (ASPD) Income Statement Analysis – Financial Results
Complete financial analysis of BioNxt Solutions Inc. (XPHYF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioNxt Solutions Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Faith, Inc. (4295.T) Income Statement Analysis – Financial Results
- Kenadyr Metals Corp. (KNDYF) Income Statement Analysis – Financial Results
- Alphax Food System Co., Ltd (3814.T) Income Statement Analysis – Financial Results
- Sinochem International Corporation (600500.SS) Income Statement Analysis – Financial Results
- Mercury NZ Limited (MGHTF) Income Statement Analysis – Financial Results
BioNxt Solutions Inc. (XPHYF)
About BioNxt Solutions Inc.
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Xphyto Therapeutics makes key appointments as it progresses its biosensor and diagnostic products including for the detection of COVID-19
Xphyto Therapeutics makes appointments as it progresses its biosensor and diagnostic products including for the detection of COVID-19
XPhyto progressing its scientific approach to cannabis-based medicine and helping in the coronavirus fight
XPhyto epilepsy clinical trial planned in 2022 with its proprietary fast-dissolving CBD oral strips
XPhyto Therapeutics completes strategic acquisition of 3a-diagnostics GmbH
XPhyto Therapeutics closes its private placements for gross proceeds of C$7M
XPhyto Therapeutics appoints Joseph Meagher as its chief financial officer
XPhyto Therapeutics announces appointment of Professor Dr Thomas Beckert as managing director of its XP Diagnostics subsidiary; launches fund-raising
XPhyto Reports Development Update for its Drug Delivery Business
Xphyto Announces Engagement of Consultants for Marketing and Promotional Activities
Source: https://incomestatements.info
Category: Stock Reports